Poster Presentation

Enhanced therapeutic antibodies and antibody-drug conjugates refractory to immunosuppressive ICAM-1

 

Poster Presentation

CA125 immunosuppresses CD19/CD20 antibodies and bispecifics, while NAV-006 escapes this mechanism

 

Publication

NAV-001, antibody-drug conjugate targeting mesothelin and counteracting CA125 inhibitory effects

 

Publication

NAV-003, Bispecific Targeting Mesothelin With Improved Cytotoxicity Against Humoral Immunosuppressed Tumors

 

Publication

NAV-006, next-gen rituximab with enhanced effector function by counteracting CA125 immunosuppression

 

Poster Presentation

The ADC NAV-001 targets mesothelin, deploys a novel payload, and is refractory to CA125 inhibition

 

Poster Presentation

HIO-3, a tumor-produced protein that binds the human IgG1 Fc CH3 domain and suppresses ADCC and CDC

 

Poster Presentation

NAV-003, Bispecific Targeting Mesothelin With Improved Cytotoxicity Against Humoral Immunosuppressed Tumors

 

Poster Presentation

BRITE Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression

 

Publication

CA125 suppresses ADCC via direct antibody binding and suppressed Fc-γ receptor engagement